Partnerships for Vaccines Forum
PATH’s 40+ years of transformative innovation

Steve Davis
President & CEO, PATH
PATH is a global team of innovators working to eliminate health inequities so people, communities, and economies can thrive.
Today, we are a global team of 1,500+, working in 70+ countries.
Specializing in designing, developing, and scaling solutions in five core areas:

- Vaccines
- Diagnostics
- Drugs
- Devices
- Health systems
PATH VACCINES - Center for Vaccine Innovation & Access (CVIA)

- Pre-clinical & Clinical Strategies, Partnerships & Support
- Vaccine Development Partnerships Across Value Chain, Including PQ Support
- Delivery & Cold Chain Tools
- Immunization Data and Digital Tools
- Policy, Advocacy, Market Shaping and Support
- Introduction Design & Studies
PDP - Product Development Partnership

A unique, non-profit business model bringing together public, private, academic and philanthropic sectors to develop technologies for global health. PDPs pave the way for new research on infectious diseases and accelerate the development of safe and effective vaccines, drugs and diagnostics for the most vulnerable populations as quickly and cheaply as possible.

- Sharing the risk
- Sharing the cost
PATH CVIA in action

**Priming a local manufacturer to fill a critical market gap**

PATH helped Bharat Biotech of India build the technical capacity to produce a high-quality, low-cost rotavirus vaccine. ROTAVAC® is a success story for improving affordable vaccine supply and tackling diarrhea in India and around the world.

**Developing and introducing a vaccine in record time**

In partnership with the WHO and Serum Institute of India, PATH helped develop and deliver MenAfriVac®, a vaccine developed specifically for Africa. The vaccine has virtually eliminated group A meningitis wherever it’s been introduced.

**Improving supply and accessibility for polio eradication**

PATH provided technical assistance to Beijing Bio-Institute Biological Products in the key, early stages of WHO prequalification for its new bivalent oral polio vaccine. The vaccine will meet increased demand during this critical phase of polio eradication.
PATH Vaccines portfolio* includes over two dozen vaccines in development and use across 17 disease targets

* Portfolio snapshot current as of June 2018; does not include new/ongoing proposal development work in dengue, Zika, or Ebola, nor ongoing support to the Expanded Programme on Immunization in multiple countries.
All of our work is built on trusted partnerships

MNCs & Research Centers
Public & Private Funders
Developing Country Manufacturers
Other PDPs & NGOs
New Partners: MRI, CEPI & Others
A 15-year, multi-sector partnership became a turning point in the battle to protect children against Japanese Encephalitis
A brief introduction to Japanese encephalitis
Partnerships for Vaccines' Forum
A historic moment.

WHO prequalification of CDIBP’s JE vaccine signaled China’s emergence in the global vaccine marketplace.
Over the past 15 years, PATH has worked with Japanese encephalitis-endemic countries to introduce and expand JE immunization programs, reaching around 300 million people.
300 million
Children vaccinated against JE
Partnerships for Vaccines’ Forum

Photos: (clockwise from left) PATH/Aaron Joel Santos, PATH/Rocky Prajapati, PATH/Rocky Prajapati, Bill & Melinda Gates Foundation

Partnerships for Vaccines’ Forum

Photos: (clockwise from left) PATH/Aaron Joel Santos, PATH/Rocky Prajapati, PATH/Rocky Prajapati, Bill & Melinda Gates Foundation
“Mind the gap”: A second “valley of death”?
Second Valley of Death – Implementation Gap

Translation gap

Implementation gap

Discovery Preclinical Phase I-III Registration WHO policy & PQ Implementation studies Financing & Procurement Uptake

Implementation gap